AU2725988A - Derivatives of lincosaminide antibiotics - Google Patents
Derivatives of lincosaminide antibioticsInfo
- Publication number
- AU2725988A AU2725988A AU27259/88A AU2725988A AU2725988A AU 2725988 A AU2725988 A AU 2725988A AU 27259/88 A AU27259/88 A AU 27259/88A AU 2725988 A AU2725988 A AU 2725988A AU 2725988 A AU2725988 A AU 2725988A
- Authority
- AU
- Australia
- Prior art keywords
- derivatives
- lincosaminide
- antibiotics
- lincosaminide antibiotics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/14—Acyclic radicals, not substituted by cyclic structures attached to a sulfur, selenium or tellurium atom of a saccharide radical
- C07H15/16—Lincomycin; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12350987A | 1987-11-20 | 1987-11-20 | |
US123509 | 1987-11-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2725988A true AU2725988A (en) | 1989-06-14 |
Family
ID=22409100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU27259/88A Abandoned AU2725988A (en) | 1987-11-20 | 1988-11-07 | Derivatives of lincosaminide antibiotics |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2725988A (en) |
WO (1) | WO1989004672A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994014437A1 (en) * | 1992-12-21 | 1994-07-07 | Ophidian Pharmaceuticals, Inc. | Prevention and treatment of sepsis |
EP0638583A1 (en) * | 1993-08-13 | 1995-02-15 | Hoechst Aktiengesellschaft | Aminosugar active substances, a process for their preparation and use as pharmaceuticals |
US7199105B2 (en) | 2002-08-15 | 2007-04-03 | Vicuron Pharmaceuticals, Inc. | Lincomycin derivatives possessing antibacterial activity |
CA2493799A1 (en) | 2002-08-15 | 2004-02-26 | Vicuron Pharmaceuticals, Inc. | Lincomycin derivatives possessing antibacterial activity |
US7256177B2 (en) | 2003-06-17 | 2007-08-14 | Vicuron Pharmaceuticals, Inc. | Lincomycin derivatives possessing antibacterial activity |
US7199106B2 (en) | 2003-06-17 | 2007-04-03 | Vicuron Pharmaceuticals, Inc. | Lincomycin derivatives possessing antimicrobial activity |
US7361743B2 (en) | 2004-02-11 | 2008-04-22 | Pfizer Inc | Lincomycin derivatives possessing antibacterial activity |
CN106074384A (en) * | 2016-08-08 | 2016-11-09 | 甘肃新天马制药股份有限公司 | A kind of pirlimycin micellar preparation and preparation method thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4376765A (en) * | 1980-03-31 | 1983-03-15 | Institut International De Pathologie Cellulaire Et Moleculaire | Medicaments, their preparation and compositions containing same |
US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
FR2570278B1 (en) * | 1984-09-14 | 1987-02-13 | Pasteur Institut | COMPOSITIONS AND METHOD FOR PROTECTING T CELLS FROM THE ETIOLOGICAL AGENT OF LYMPHADENOPATHIES AND ACQUIRED IMMUNODEPRESSION SYNDROME |
-
1988
- 1988-11-07 WO PCT/US1988/003865 patent/WO1989004672A1/en not_active Application Discontinuation
- 1988-11-07 AU AU27259/88A patent/AU2725988A/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO1989004672A1 (en) | 1989-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU7162487A (en) | Cephalosporin derivatives | |
AU5578390A (en) | Dioxothiazolidine derivatives | |
AU1741788A (en) | Azolylmethyl-cyclopropyl derivatives | |
AU2753588A (en) | New derivatives | |
AU1313288A (en) | Avermectin derivatives | |
AU1465688A (en) | Pyrrole derivatives | |
AU7591787A (en) | Cephalosporin derivatives | |
AU2055488A (en) | 7-Acylaminocephalosporin derivatives | |
AU3704684A (en) | Cephalosporin antibiotics | |
AU6314890A (en) | Novel cephalosporin derivatives | |
AU2150088A (en) | Isoxazole-beta-carboline derivatives | |
AU613543B2 (en) | Preparation of halofluorobenzenes | |
AU1455288A (en) | Benzazepine derivatives | |
AU555768B2 (en) | Penam derivatives | |
AU8163187A (en) | Novel cephalosporin derivatives and their crystalline derivatives | |
AU2725988A (en) | Derivatives of lincosaminide antibiotics | |
AU2381988A (en) | Thienopyrimidine derivatives | |
AU4552389A (en) | Preparation of n-acyl-aminomethylphosphonates | |
AU8163287A (en) | Cephalosporin derivatives | |
AU1862088A (en) | Hydroxyethyl-Azolyl derivatives | |
AU2065688A (en) | Rifamycin derivatives | |
AU1313488A (en) | Process for the preparation of nitroethene derivatives | |
AU3484789A (en) | Heteroaroylhydrazide derivatives of monocyclic lactam antibiotics | |
AU7287787A (en) | Beta-lactam antibiotics | |
AU2464488A (en) | Ginkgolide derivatives |